Methods and compositions to reduce liver damage associated with conditions or therapies that affect the immune system
AssigneeThe University of Chicago
InventorYang-Xin Fu
Life of this patent
Estimating the term…
Abstract
One side-effect arising from the use of antibodies against TNF receptor family members as therapeutics can be liver damage which precludes the completion of clinical trial. A novel LT-dependent pathway is described that mediates liver cell injury in several disease models.
Claims19
A method to reduce liver damage in a mammal, the method comprising administering to the mammal an agent that interferes with the LT or TNF pathways.
A composition comprising an agent that interferes with a component of the LT pathway and a therapeutic agent directed at a disease or condition.
A composition comprising an agent that interferes with a component of the TNF pathway and a therapeutic agent directed at a disease or condition.
A pharmaceutical composition to alleviate hepatic injury induced by therapies, the composition comprising an agonistic CD137 antibody and an anti-TNF or anti-LT therapy.
The pharmaceutical composition of claim 21 wherein the agonistic CD137 antibody is BMS-663513.
Dependencies are inferred from the claim text.